SG Americas Securities LLC Invests $27,000 in Century Therapeutics, Inc. (NASDAQ:IPSC)

SG Americas Securities LLC acquired a new stake in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 16,081 shares of the company’s stock, valued at approximately $27,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its position in Century Therapeutics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after buying an additional 9,500 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Century Therapeutics by 141.7% during the second quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after acquiring an additional 44,155 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Century Therapeutics by 56.0% during the second quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after acquiring an additional 18,828 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Century Therapeutics by 110.1% during the second quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock valued at $380,000 after purchasing an additional 78,088 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its stake in Century Therapeutics by 191.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 293,941 shares of the company’s stock valued at $1,229,000 after purchasing an additional 192,915 shares in the last quarter. 50.20% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on IPSC. HC Wainwright lowered their price target on Century Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, August 15th. Rodman & Renshaw assumed coverage on shares of Century Therapeutics in a research report on Thursday, August 8th. They issued a “buy” rating and a $6.00 target price for the company.

Century Therapeutics Stock Performance

IPSC opened at $1.36 on Wednesday. The company has a market cap of $114.92 million, a PE ratio of -0.62 and a beta of 1.36. The stock has a 50-day moving average of $1.59 and a 200-day moving average of $2.31. Century Therapeutics, Inc. has a 52-week low of $1.28 and a 52-week high of $5.51.

Century Therapeutics (NASDAQ:IPSC) last announced its earnings results on Thursday, August 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.12. The firm had revenue of $0.77 million during the quarter, compared to analysts’ expectations of $0.55 million. Century Therapeutics had a negative return on equity of 60.60% and a negative net margin of 6,434.23%. On average, research analysts predict that Century Therapeutics, Inc. will post -1.8 earnings per share for the current year.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.